405 related articles for article (PubMed ID: 27721262)
1. The efficacy and safety of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population: A single institution experience.
Xu Y; Wang Z; Liu G; Zheng X; Wang Y; Feng W; Lai X; Zhou X; Li P; Ma H; Wang J; Hu X; Chen M
J Cancer Res Ther; 2016 Oct; 12(Supplement):82-88. PubMed ID: 27721262
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical outcome of intensity-modulated radiation therapy for locally advanced esophageal squamous cell carcinoma.
Ge X; Yang X; Lu X; Wen W; Zhen F; Ye H; Zhu H; Cao Y; Zhang S; Cheng H; Ma J; Yang B; Dai S; Guo Q; Cai J; Sun X
Tumori; 2015; 101(2):168-73. PubMed ID: 25791535
[TBL] [Abstract][Full Text] [Related]
4. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in Chinese population: A retrospective study.
Xu Y; Zheng X; Bai X; Li P; Ma H; Wang J; Hu X; Chen M
Oncotarget; 2017 Jul; 8(30):49084-49092. PubMed ID: 28467775
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
Lan W; Lihong L; Chun H; Shutang L; Qi W; Liang X; Xiaoning L; Likun L
Strahlenther Onkol; 2022 Sep; 198(9):802-811. PubMed ID: 35029718
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase III study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma.
Lertbutsayanukul C; Prayongrat A; Kannarunimit D; Chakkabat C; Netsawang B; Kitpanit S
Strahlenther Onkol; 2018 May; 194(5):375-385. PubMed ID: 29302704
[TBL] [Abstract][Full Text] [Related]
8. Definite intensity-modulated radiotherapy with concurrent chemotherapy more than 4 cycles improved survival for patients with locally-advanced or inoperable esophageal squamous cell carcinoma.
Hsieh HY; Hsu CP; Yeh HL; Chuang CY; Lin JF; Chang CF
Kaohsiung J Med Sci; 2018 May; 34(5):281-289. PubMed ID: 29699635
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Radiat Oncol; 2017 Aug; 12(1):131. PubMed ID: 28810885
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study.
Yu WW; Zhu ZF; Fu XL; Zhao KL; Mao JF; Wu KL; Yang HJ; Fan M; Zhao S; Welsh J
Strahlenther Onkol; 2014 Oct; 190(11):979-86. PubMed ID: 24609941
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
[TBL] [Abstract][Full Text] [Related]
12. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events.
Songthong AP; Kannarunimit D; Chakkabat C; Lertbutsayanukul C
Radiat Oncol; 2015 Aug; 10():166. PubMed ID: 26253488
[TBL] [Abstract][Full Text] [Related]
14. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma: treatment results from a prospective observational study.
Li HX; Liu J; Cheng Y; Liu MN; Fang WT; Lv CX
Dis Esophagus; 2018 May; 31(5):. PubMed ID: 29294022
[TBL] [Abstract][Full Text] [Related]
16. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series.
Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U
Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma without hypopharyngeal invasion: dose distribution and clinical outcome.
Ishida Y; Sakanaka K; Fujii K; Itasaka S; Mizowaki T
J Radiat Res; 2019 Jul; 60(4):517-526. PubMed ID: 31083715
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Zhao C; Lin L; Liu J; Liu R; Chen Y; Ge F; Jia R; Jin Y; Wang Y; Xu J
Oncotarget; 2016 Aug; 7(35):57310-57316. PubMed ID: 28087951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]